Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Public comment periods — page 3

120 consultations carrying 1,332 signed submissions. Every submission has a declared interest, a secretariat response and a disposition.

Consultations

120 documents · page 3 of 6
  • CEI-CP-035ClosedEvidence synthesis27 Oct 2025 – 08 Dec 2025

    Consultation on the draft scoping review of melanocortin receptor agonists, which maps the evidence across approved indications and the uses for which these compounds are supplied outside a regulated route. The review is scoping because…

    11 submissions1 not accepted
  • CEI-CP-018ClosedEvidence synthesis12 Oct 2025 – 23 Nov 2025

    Consultation on the draft safety review of delayed gastric emptying and residual gastric content in patients receiving an incretin receptor agonist who present for procedural sedation. The review assesses a signal drawn largely from…

    15 submissions1 not accepted
  • CEI-CP-057ClosedCompound monograph16 Oct 2025 – 15 Nov 2025

    Consultation on the draft monograph for Ipamorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    10 submissions1 not accepted
  • CEI-CP-014ClosedMethodological standard12 Oct 2025 – 09 Nov 2025

    Consultation on the draft standard for bacterial endotoxin testing of peptide presentations, which specifies the performance a determination must achieve and the interference testing required before a result can be interpreted. The draft…

    12 submissions1 not accepted
  • CEI-CP-105ClosedEvidence synthesis06 Oct 2025 – 03 Nov 2025

    Consultation on the draft of this analytical evidence review, which registers the question: What proportion of certificates of analysis supplied with research peptides contain the fields required to interpret the reported purity figure?

    8 submissions
  • CEI-CP-043ClosedCompound monograph31 Jul 2025 – 29 Sep 2025

    Consultation on the draft monograph for CagriSema (cagrilintide with semaglutide), which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate…

    5 submissions1 not accepted
  • CEI-CP-008ClosedEvidence synthesis30 Jul 2025 – 28 Sep 2025

    Consultation on the draft synthesis of weight trajectory after an incretin receptor agonist is stopped. The contributing evidence is drawn principally from the randomised withdrawal designs in STEP 4, reported in JAMA in 2021, and…

    16 submissions2 not accepted
  • CEI-CP-081ClosedCompound monograph29 Jul 2025 – 27 Sep 2025

    Consultation on the draft monograph for Thymalin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…

    10 submissions1 not accepted
  • CEI-CP-074ClosedCompound monograph24 Jul 2025 – 18 Sep 2025

    Consultation on the draft monograph for Semax, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that rating…

    15 submissions
  • CEI-CP-080ClosedCompound monograph21 Jul 2025 – 15 Sep 2025

    Consultation on the draft monograph for Tesamorelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    15 submissions3 not accepted
  • CEI-CP-092ClosedMethodological standard21 Jul 2025 – 15 Sep 2025

    Consultation on the draft of CEI-MS-12, which specifies the performance a determination must achieve for content and states what the resulting figure does not establish. The draft states performance rather than prescribing a fixed…

    15 submissions2 not accepted
  • CEI-CP-027ClosedEvidence synthesis10 Aug 2025 – 09 Sep 2025

    Consultation on the draft analytical evidence review of published surveys of unregulated peptide supply. The review assesses what such surveys establish, and records that the great majority of them cannot establish the provenance of the…

    14 submissions2 not accepted
  • CEI-CP-068ClosedCompound monograph07 Jul 2025 – 01 Sep 2025

    Consultation on the draft monograph for NAD+ (nicotinamide adenine dinucleotide), which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low…

    9 submissions2 not accepted
  • CEI-CP-031ClosedCompound monograph14 Jul 2025 – 25 Aug 2025

    Consultation on the draft monograph for danuglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist whose development programme was discontinued. The draft records the discontinuation and treats the resulting evidence as…

    3 submissions
  • CEI-CP-045ClosedCompound monograph22 Jul 2025 – 21 Aug 2025

    Consultation on the draft monograph for DSIP, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that…

    4 submissions
  • CEI-CP-061ClosedCompound monograph17 Jul 2025 – 16 Aug 2025

    Consultation on the draft monograph for Liraglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at high certainty and states the basis for that…

    8 submissions
  • CEI-CP-095ClosedMethodological standard08 Apr 2025 – 03 Jun 2025

    Consultation on the draft of CEI-MS-09, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not establish. The draft states performance rather than prescribing a fixed…

    13 submissions2 not accepted
  • CEI-CP-006ClosedCompound monograph03 May 2025 – 31 May 2025

    Consultation on the second version of the tirzepatide monograph, which incorporates the obesity evidence from SURMOUNT-1, reported in the New England Journal of Medicine in 2022, the withdrawal evidence from SURMOUNT-4, reported in JAMA in…

    15 submissions1 not accepted
  • CEI-CP-033ClosedDocument series28 Apr 2025 – 28 May 2025

    Consultation on the comparison table that presents supplier dossiers side by side. The draft table shows only fields verified from a document the Institute holds, and the consultation was principally concerned with whether a sortable table…

    14 submissions1 not accepted
  • CEI-CP-111ClosedEvidence synthesis28 Apr 2025 – 26 May 2025

    Consultation on the draft of this methodological review, which registers the question: To what extent does a change in body weight predict a change in the clinical outcomes for which weight reduction is undertaken?

    9 submissions1 not accepted

page 3 of 6

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.